Assay for detection and/or quantifying a mammalian IgA antibody response to Epstein-Barr virus membrane antigen using EBV-MA gp 350/220 lacking the transmembrane anchor domain
AssigneeE. I. Du Pont de Nemours and Company
InventorsPaul John Durda, Elliott Dan Kieff, Gary Richard Pearson, Harvey Rabin, Marcia Delaney Sullivan
Life of this patent
Estimating the term…
Abstract
This disclosure concerns an assay for detecting and/or quantifying a mammalian IgA antibody response to EBV-MA with an immobilized EBV-MA gp 350/220 lacking the transmembrane anchor domain.
Claims18
An assay for detecting a mammalian IgA antibody response to Epstein-Barr Virus Membrane Antigen EBV-MA which comprises:
- (a) incubating a sample suspected to contain EBV-MA antibodies with an immobilized recombinant form of EBV-MA gp350/220 wherein said EBV-MA is truncated gp350/220 secreted by a mammalian cell expression system and further wherein said truncated gp350/220 lacks the transmembrane anchor domain;
- and
- (b) detecting the product step (a) by reacting the product of step (a) with a labeled detector reagent which specifically binds mammalian IgA antibodies specific for EBV-MA, thereby detecting said mammalian antibody response to EBV-MA.
An assay for measuring a mammalian IgA antibody response to Epstein-Barr Virus Membrane Antigen EBV-MA which comprises:
- (a) incubating a sample suspected to contain EBV-MA antibodies with an immobilized recombinant form of EBV-MA gp350/220 wherein said EBV-MA is truncated gp350/220 secreted by a mammalian cell expression system and further wherein said truncated gp350/220 lacks the transmembrane anchor domain;
- and
- (b) reacting the product of step (a) with a labeled detector reagent which specifically binds mammalian IgA antibodies specific for EBV-MA;
- (c) assaying for the amount of product formed in step (b);
- and
- (d) comparing the amount of said product formed with a standard curve so as to indicate the amount of EBV-MA antibodies present in the sample.
An assay for detecting a human IgA antibody response to Epstein-Barr Virus Membrane Antigen EBV-MA which comprises:
- (a) incubating a sample suspected to contain EBV-MA antibodies with an immobilized recombinant form of EBV-MA gp350/220 wherein EBV-MA is a truncated gp350/220 secreted by a mammalian cell expression system and further wherein said truncated gp350/220 lacks the transmembrane anchor domain;
- and
- (b) detecting the product of step (a) by reacting the product step (a) with a labeled detector reagent which specifically binds human IgA antibodies specific for EBV-MA, thereby detecting said human IgA antibody response to EBV-MA.
An assay for measuring a human IgA antibody response to Epstein-Barr Virus Membrane Antigen EBV-MA which comprises:
- (a) incubating a sample suspected to contain EBV-MA antibodies with an immobilized recombinant form of EBV-MA gp350/220 wherein said EBV-MA is a truncated gp350/220 secreted by a mammalian cell expression system and further wherein said truncated gp350/220 lacks the transmembrane anchor domain;
- and
- (b) reacting the product of step (a) with a labeled detector reagent which specifically binds mammalian IgA antibodies specific for EBV-MA;
- (c) assaying for the amount of product formed in step (b);
- and
- (d) comparing the amount of said product formed with a standard curve so as to indicate the amount of human IgA EBV-MA antibodies present in the sample.
Dependencies are inferred from the claim text.